Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Change in Receivables: 2022-2025

Historic Change in Receivables for Axsome Therapeutics (AXSM) over the last 3 years, with Sep 2025 value amounting to -$2.3 million.

  • Axsome Therapeutics' Change in Receivables fell 161.75% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.4 million, marking a year-over-year increase of 58.51%. This contributed to the annual value of $47.2 million for FY2024, which is 17.40% down from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' Change in Receivables is -$2.3 million, which was down 106.19% from $37.4 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Change in Receivables ranged from a high of $37.4 million in Q2 2025 and a low of -$2.3 million during Q3 2025.
  • Its 3-year average for Change in Receivables is $14.4 million, with a median of $16.4 million in 2023.
  • The largest annual percentage gain for Axsome Therapeutics' Change in Receivables in the last 5 years was 193.21% (2025), contrasted with its biggest fall of 161.75% (2025).
  • Over the past 4 years, Axsome Therapeutics' Change in Receivables (Quarterly) stood at $17.4 million in 2022, then dropped by 5.70% to $16.4 million in 2023, then increased by 9.14% to $17.9 million in 2024, then plummeted by 161.75% to -$2.3 million in 2025.
  • Its last three reported values are -$2.3 million in Q3 2025, $37.4 million for Q2 2025, and $19.4 million during Q1 2025.